Jane Street
ANRO icon

Jane Street’s Alto Neuroscience ANRO Stock Holding History

Jane Street’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Buy
48,000
+300
+0.6% +$5.56K ﹤0.01% 6327
2025
Q4 		$849K Buy
+47,700
New +$601K ﹤0.01% 6478

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street's ANRO Position: Q1 2026 in Review

Jane Street reduced its Alto Neuroscience (ANRO) stake by 85% in Q1 2026, selling an estimated $3.04M and leaving 30,058 shares worth $676K. The position accounts for ﹤0.01% of the portfolio, ranked #7344.

Jane Street first reported a position in ANRO in Q1 2024 and has held it in 7 quarters since. The position peaked at $3.45M in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Jane Street held 30,058 shares of Alto Neuroscience worth $676K as of Q1 2026.
  • Jane Street sold 163,983 Alto Neuroscience shares in Q1 2026, an estimated $3.04M.
  • Alto Neuroscience made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7344 holding.
  • Jane Street first reported a position in Alto Neuroscience in Q1 2024 and has held it in 7 quarters since.
  • Jane Street's Alto Neuroscience position peaked at $3.45M in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.